Emerging Pharmaceutical Market - Czech Republic – Planned Healthcare Reform Plans Forecast to Slow Growth Rates

GBI Research’s new report, Emerging Pharmaceutical Market - Czech Republic – Planned Healthcare Reform Plans Forecast to Slow Growth Rates provides in-depth analysis of trends, issues and challenges in the pharmaceutical market in the Czech Republic. The report analyzes overall pharmaceutical and outsourcing market structure in the Czech Republic. The report provides competitive benchmarking for the leading companies and analyzes the M&A and strategic partnerships that shape the Czech pharmaceutical market. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts. The Czech Republic pharmaceutical market is one of the most attractive markets in Central and Eastern Europe. The availability of cost effective skilled labour, high quality infrastructure and EU harmonious regulations are the main reasons for the fast growth of the Czech pharmaceutical industry. Most local drug manufacturers and distributors are owned by big international pharmaceutical firms. GBI Research valued the Czech pharmaceutical market at $3.1 billion in 2010, which grew with a compound annual growth rate (CAGR) of 11.7% from 2004 to 2010. The Czech healthcare sector will witness many new healthcare reforms in the coming years, with the primary objective of reducing growing drug expenditure. In response to these healthcare policies, the Czech pharmaceutical market is expected to witness a lower growth rate in forecast period. GBI Research has analyzed that in 2011, generics had a share of over 50% of the Czech pharmaceutical market. Czech government reforms encourage the manufacture and use of generic drugs, in an attempt to limit drug expenditure and provide low cost-effective public healthcare. Government healthcare policies, coupled with numerous active generic manufacturing companies in the country, will increase the share of generics in the market during the forecast period. The Czech Republic is showing a moderate recovery from the economic downturn in 2009; increased industrial outputs and government structural reforms in various sectors including healthcare have contributed to the growth. GBI Research analyzed that the new healthcare reform policy which is expect to be implemented from 2012, with elements of “standard” and “above standard” care, in which patients pay more for above standard (expensive drugs and services) care and an increase in co-payments from the patients, reduces healthcare affordability for individual patients and will pose a major challenge to the Czech pharmaceutical market.

Scope

• Overall pharma, biotech and outsourcing market structure in Czech Republic
• Czech Republic pharmaceutical market characterization, including market size, major regulatory bodies, pricing and reimbursement issues, major distribution channel and intellectual property rights.
• Czech Republic CRO market growth.
• Analysis of the leading segments within the Czech Republic pharmaceutical industry.
• Key market drivers and restraints that have a significant impact on the Czech Republic pharmaceutical market.
• Competitive benchmarking of leading companies in pharmaceutical and CRO markets.
• Key M&A activities and strategic partnership deals that have taken place between 2009 and mid 2011.

Reasons to Buy

• Develop market entry and market expansion strategies by identifying the leading emerging markets poised for strong growth.
• Devise a more tailored country strategy through the understanding of key drivers and barriers of the country’s pharmaceutical market.
• Develop key strategic initiatives by understanding the key focus areas of leading companies.
• Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships.